Aurora Cannabis Stock (TSX: ACB) (NYSE: ACB) - Investor Dashboard


Aurora Cannabis
TSX: ACB
NYSE: ACB
Market Focus: Global
Classification: Vertically Integrated
Country: Canada
Employees: ~3000 as of 09/2019
Established: 2013
Interim CEO: Michael Singer

Summary

Fiscal Year-End: June 30
Licensed Facilities: 15
Dried Flower: Production and Sale
Extracts: Production and Sale
Number of Patients: 91,000+ at 11/2019
Headquarters: Edmonton, Alberta

Financials (12/31/19)

Cash on hand: $156.3 million
Fixed Investment: $1.002 billion
Shareholders’ Equity: $3.844 billion
Net Revenue – Last Quarter: $56.0 million
Adj. Gross Margin: 40.7%
EPS : -$1.18

Capital Structure (01/31/20)

Last Equity Fin: US$81.2 million at US$3.78
Basic Shares: 1.17 billion
Warrants: 21.8 million
Options: 70.3 million
Diluted Shares: 1.31 billion

Company Brief

Aurora is one of the world’s largest and fastest growing cannabis companies. Following the acquisition of MedReleaf, the company has more than 3,000 employees, 15 facilities (two EU GMP certified), and a funded annual production capacity of more than 625,000 kilograms per year.

The Company is vertically integrated and horizontally diversified across every key segment of the cannabis value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis, and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company’s purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. Aurora’s growing constellation of subsidiaries and strategic partnerships provide differentiation in terms of geographic reach, production, technology, product offering, and execution.

Featured Video

Home Grown: The Making of Aurora’s Flagship Retail Experience

With a growing number of countries adopting medical cannabis legislation, the Company has embarked on an aggressive international expansion strategy that currently sees Aurora with operations and/or sales in 25 countries across five continents.


Differentiators

Canadian Operations

  • 15 global production facilities in operation with three EU GMP certified
  • Significant opportunities in the medical, consumer, and hemp-derived CBD categories
  • Extensive use of automation to drive sustainability and low-cost advantage
  • Ownership of CanvasRx, the largest operator of cannabis clinics in Canada with over 35 clinics open
  • Strong product portfolio brands including Aurora, CanniMed, MedReleaf, San Rafael ’71, Woodstock, AltaVie, Bidol, Plant Hemp, and Roar Sports
  • Same-day delivery in Alberta and innovative mobile ordering app
  • Supply agreements across 12 provinces and territories; a robust distribution network serving 98% of Canada’s population
  • Agreements with PharmaChoice, Pharmasave, and Shoppers Drug Mart to distribute and sell medical cannabis
  • 40 clinical studies completed or ongoing, over 91,000 medical patients served, and more than 100 patents filed
  • Partnerships with leading institutions and universities
  • 17 strategic acquisitions and partnerships since August 2016
  • Strong and stable gross margin of 58% and $0.85 cash cost to produce per gram of dried cannabis in Q1 2020
  • 10,000-square-foot flagship retail store located at West Edmonton Mall, the largest mall in North America

Global Operations

  • Active in five continents and 25 countries
  • 22.9% ownership of Australia’s Cann Group (ASX: CAN)and 51% ownership of Aurora Nordic in Denmark
  • International partner of choice in markets such as Italy, Germany, Malta, and Poland
  • Wholly owned subsidiary ICC Labs gives the company a platform in Latin America
  • Supply agreements in the Czech Republic, Italy, South Africa, Luxembourg, Mexico, United Kingdom, and Germany
  • 51% ownership interest in Gaia Pharma Lda. to establish a local facility to produce medical cannabis and derivative product in Portugal
  • Health UK granted Aurora approval for its first shipment of medical cannabis into the UK from Canada under its new legal framework effective as of November 1, 2018
  • Structured investment in spin-off Australis Capital, which positions the company to benefit from eventual U.S. legalization
  • In Q4 2019, the Office for Registration of Medicinal Products, Medical Devices and Biocides in Poland, released the marketing authorization for four of Aurora’s products enabling Aurora to expand its product offering in Poland
  • Integrated operating unit Aurora Hemp drives the company’s global hemp strategy

Institutional Analyst Coverage

MICHAEL S. LAVERY
PiperJaffray

MATT BOTTOMLEY
Canaccord Genuity

BRETT HUNDLEY
Seaport

MARTIN LANDRY
GMP Securities

GRAEME KREINDLER
Eight Capital

VIVIEN AZER
Cowen and Company

CHRISTOPHER CAREY
Bank of America Merrill Lynch

PABLO ZUANIC
Cantor Fitzgerald

DOUGLAS MIEHM
RBC Capital Markets

JASON ZANDBERG
PI FINANCIAL

TAMY CHEN
BMO Nesbitt Burns

OLIVER ROWE
Scotiabank

GREG MCLEISH, CFA
Mackie Research

NIKOLAAS FAES
Bryan Garnier & Co

ROB WERTHEIMER
Melius Research

W. ANDREW CARTER
Stifel Financial Corp. 


Curated Stories & News


Visit Aurora Cannabis
at www.auroramj.com.

New Cannabis Ventures in partnership with due diligence platform 420Investor, is the definitive source for fact-based, data-driven, financial information and relevant company news for qualified publicly traded cannabis companies. NCV extracts and parses only the most important content. Information is provided “as is” and solely for informational purposes, not for trading or advice. Aurora Cannabis is a client of NCV Media, LLC. Read our full disclaimer.